Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Leukemia, Myeloid, Acute
Interventions: BAY1436032; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Buffalo, New York • New York, New York • The Bronx, New York + 4 more

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Blood Coagulation Disorders, Hemophilia A
Interventions: Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Orange, California • Sacramento, California • Tampa, Florida + 4 more

Conditions: Graft Versus Host Disease
Interventions: RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Regimen, Allogeneic Bone Marrow Transplantation, Methotrexate, Mofetil Mycophenolate, sirolimus; Drug · Procedure
Lead sponsor: Regimmune Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 6
States / cities: San Diego, California • Stanford, California • Tampa, Florida + 3 more

Conditions: Malignant Lung Neoplasm
Interventions: Standard Follow-Up Care, Caregiver-Related Intervention or Procedure, Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Duarte, California

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions: KRT-232, Cytarabine, Decitabine; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more

Conditions: Cancer
Interventions: SCC, Nurse Practitioner, DSS, AT, Symptom Severity; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acute Pain
Interventions: ETR028, ETR029, [ETR028 + ETR029] or HCBT; Drug
Lead sponsor: Elysium Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Migraine, Vestibular Migraine, Vestibular Schwannoma, Motion Sickness, Dizziness, Vestibular Disorder
Interventions: Temporal Binding Adaptation - PSS training, Temporal Binding Adaptation - PSS adaptation with VI stimulation, Chronic Motion-modulated Stimulation; Behavioral
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 8 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Posttraumatic Stress Disorder, Spinal Cord Injuries
Interventions: Prolonged Exposure Therapy; Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cerebral Palsy, Central Nervous System Diseases, Brain Damage, Chronic
Interventions: Power training combined with interval treadmill training, Strength training combined with traditional treadmill training; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 10 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New Orleans, Louisiana • Seattle, Washington

Conditions: Substance Use Disorders
Interventions: IntACT, Usual Care; Behavioral
Lead sponsor: Michael Incze; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Solid Tumor
Interventions: DS5361b, Pembrolizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Sarasota, Florida • Providence, Rhode Island • Irving, Texas + 2 more

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions: CNTY-101, IL-2, Lymphodepleting Chemotherapy; Biological · Drug
Lead sponsor: Century Therapeutics, Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Spinal Tumor
Interventions: Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation, Questionnaires; Radiation · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions: PF-06801591; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 24
States / cities: Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more

Conditions: Nocturnal Polyuria
Interventions: Baseline EpiNP survey, Bladder diary, Testing of EpiNP baseline survey, bladder diary and a qualitative interview, No other intervention; Diagnostic Test · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 10,190 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Agitation,Psychomotor, Dementia
Interventions: Sublingual film containing Dexmedetomidine, Sublingual Placebo Film; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 65 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Homestead, Florida • Miami Lakes, Florida • Springfield, Massachusetts + 2 more

Conditions: Traumatic Brain Injury
Interventions: Personalized Augmented Cognitive Training (PACT), Enhanced Treatment As Usual; Behavioral
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 18 Years to 55 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: San Diego, California

Conditions: Multiple Myeloma
Interventions: CLN-619; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more

Conditions: Obesity, Heart Diseases
Interventions: Physical Activity Program; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Columbia, South Carolina • San Antonio, Texas

Conditions: Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions: Nivolumab, Nivolumab + Relatlimab, Ipilimumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more

Conditions: HIV
Interventions: Shine, Control; Behavioral
Lead sponsor: ISA Associates, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Alexandria, Virginia

Search by objective public record fields.

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Treatment of Supine Hypertension in Autonomic Failure

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Video-Assisted Intervention in Improving Recovery in Patients With Cancer Undergoing Lung Surgery and Caregivers

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention

Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects

Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma

Outcomes After Spinal Cord Injury (OASIS)

Power Training Combined With Interval Treadmill Training

Feasibility of an Interdisciplinary Intervention to Improve Care Transitions for Hospitalized Patients With Substance Use Disorders

A Study of DS5361b in Participants With Advanced Solid Tumors

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans with a History of TBI

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Increasing Physical Activity Among Mexican American Women (The Enlace Study)

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

Improving HIV Outcomes Among African American Transgender Women